Robert Tighe

Robert Tighe currently serves as Chief Scientific Officer at Ankyra Therapeutics since July 2023. Prior to this role, Tighe held multiple positions at TCR² Therapeutics Inc. from July 2019 to June 2023, including Vice President of Research and VP of Translational Research. Tighe's earlier experience includes serving as Vice President of Translational Immunology & Immunopharmacology, Senior Director, and Director at Compass Therapeutics LLC between December 2015 and June 2019. Tighe’s career also encompasses significant roles at EMD Serono, Inc. from January 2005 to November 2015, and earlier positions as a Research Scientist at ArQule and a Biomedical Technologist at The Jackson Laboratory. Tighe commenced a research career at MIT as a Research Assistant, focusing on gene therapy, and contributed to critical research on colorectal cancer during time spent at the Whitehead Institute.